 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C22H30N2O |
| Molar mass | 338.495 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SR-16435 is a drug which acts as a potent partial agonist at both the μ-opioid receptor and nociceptin receptor. In animal studies it was found to be a potent analgesic, with results suggestive of reduced development of tolerance and increased activity against neuropathic pain compared to classic μ-selective agonists.[1][2][3]
See also[edit]
References[edit]
- ^ Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, Toll L (February 2007). "SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice". The Journal of Pharmacology and Experimental Therapeutics. 320 (2): 934–43. doi:10.1124/jpet.106.111997. PMID 17132815. S2CID 2920534.
- ^ Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, et al. (February 2008). "Activities of mixed NOP and mu-opioid receptor ligands". British Journal of Pharmacology. 153 (3): 609–19. doi:10.1038/sj.bjp.0707598. PMC 2241792. PMID 18059322.
- ^ Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC (July 2013). "Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain". The Journal of Pharmacology and Experimental Therapeutics. 346 (1): 11–22. doi:10.1124/jpet.113.203984. PMC 3684842. PMID 23652222.